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Background: Chronic bronchitis is related to worse general health status, exacerbations and
mortality among subjects with COPD. Also less longstanding cough and phlegm may be related
to worse prognosis in COPD but this has rarely been evaluated in population-based studies.
Aim: To evaluate the relationship between productive cough, exacerbations and mortality
among subjects with and without COPD.
Method: All subjects with COPD (nZ 993) were identified together with sex- and age matched
reference subjects without obstructive lung function impairment from four population-based
cohorts in 2002e04. Baseline spirometry and structured interview including data on exacerba-
tions last 12 months were used in this study (nZ 1986) together with mortality data collected
until February 2012.
Results: Productive cough was more common in COPD than non-COPD (42.8 vs. 23.5%,
p < 0.001), more common in men than women, but associated to exacerbations in both sexes.
COPD-subjects with productive cough had the highest risk for exacerbations in both sexes and
they had a significantly increased risk for death (HR 1.48, 95% CI 1.13e1.94) also when




Subjects with COPD and productive cough 89Conclusion: Productive cough was common and increased the risk for exacerbations in both
sexes, in both COPD and non-COPD. COPD-subjects with productive cough had the highest risk
for exacerbations and a significantly higher risk for death also after adjustment for common
risk factors.
ª 2014 Elsevier Ltd. All rights reserved.Background
It has been clearly established during recent years that
COPD is not a single disease but a heterogeneous syndrome
including systemic effects. Different phenotypes have been
described [1,2], even though there are yet no generally
accepted classifications of phenotypes. Among phenotypes
based on clinical data the bronchitis phenotype deserves
special attention. Already in 1986 an increased mortality
was described among male workers with chronic phlegm
[3], supported also by later studies [4,5]. According to a
recent review the prevalence of chronic bronchitis among
subject with COPD is in the wide range of 14e74 % [6], while
a pooled prevalence of chronic bronchitis, regardless of
COPD, was estimated at 7.6% [7]. As COPD [8,9], also
chronic bronchitis seems to be an under-diagnosed condi-
tion [7,10]. Presence of chronic bronchitis among subjects
with COPD is associated with worse lung function, worse
general health status, more exacerbations [6,11] and
increased mortality [4e6] when compared to those without
chronic bronchitis.
Productive cough without fulfilling the two years interval
included in the definition of chronic bronchitis is also
common, and was reported by every third subject in the
Lung Health Study where only smokers with mild-to mod-
erate COPD were included [12]. This less long-standing
symptom was likewise related to worse outcome such as
accelerated lung function decline and increased mortality.
It is important to find simple tools, such as clinical char-
acteristics, sensitive enough to early detect signs that are
of prognostic value in COPD. However, population-based
data are scarce and possible sex differences regarding
prevalence and prognostic impact of less long-standing
bronchitis symptoms such as productive cough have hardly
been evaluated even though it is known that women are
more vulnerable to tobacco smoke increasing the risk for
COPD [13].
Within the epidemiological research programme OLIN
(Obstructive Lung Disease in Northern Sweden) studies, a
population-based cohort comprising subjects with and
without obstructive lung function impairment is followed
longitudinally [14]. The aim of this study was to evaluate
the impact of productive cough on exacerbations and
mortality among subjects with and without COPD. A further
objective was to evaluate possible sex differences.
Material & methods
The study population constituting the OLIN COPD study was
recruited from four adult population-based cohorts exam-
ined during 2002e2004. The recruitment process has beenpresented previously [14]. The study population included
1986 subjects; 993 with COPD and 993 age- and sex
matched subjects without obstructive lung function
impairment. In the current study cross-sectional data from
structured interview and spirometry performed during ex-
aminations in 2002e04 were used. Mortality data was
collected from the national mortality register from the date
of examination at recruitment until February 2012, corre-
sponding to a follow-up time in the range of eight to ten
years. The study was approved by the Regional Ethics
Committee at Umea˚ University.
Structured interview
Previously well-validated questions regarding respiratory
symptoms were included in the interview questionnaire
[5,8,15]. Productive cough was defined as affirmative
answer to the question ‘have you had cough with phlegm
most days during at least three months during the last 12
months?’. Exacerbation was defined as affirmative answer
to the question: ‘have you contacted health care due to
respiratory complaints during the last 12 months?’ Exacer-
bations were classified as ‘any exacerbation during the last
12 months’ and ‘frequent exacerbations’ defined as two or
more such events during the last 12 months. Smoking habits
were classified into the following groups: non-smokers, ex-
smokers (stopped at least one year before the baseline
visit) and current smokers. The variable ‘heart disease’
included self-reported angina pectoris, previous coronary
artery bypass surgery, previous percutaneous coronary
intervention, myocardial infarction or heart failure.
Spirometry and classification of COPD
The lung function tests were performed using a dry
spirometer, Mijnhardt Vicatest 5 by following the ATS,
American Thoracic Societies, guidelines [16]. COPD was
defined as FEV1/best of VC or FVC <0.70. Classification of
disease severity was made according to the GOLD, Global
initiative of Obstructive Lung Disease, spirometric criteria
into grade 1e4, based on FEV1 percent of predicted [17].
Swedish reference values were used [18].
Statistical analysis
Statistical calculations were made using the Statistical
Package for the Social Sciences (SPSS) software version 19.0.
A p-value of <0.05 was regarded as statistically significant.
The chi-squared test was used for bi-variate comparisons and
to test for trends. The number of missing answers was all
through low, and did not exceed 1%. Due to a low number of
90 A. Lindberg et al.subjects GOLD grades 3e4 were grouped together in the
analyses. Crude mortality was based on data collected from
baseline at recruitment in 2002e2004 until February 2012.
Risk factors for exacerbations were calculated in a multi-
variate regression model including the co-variates sex, age,
BMI, smoking habits, heart disease and non-COPD and COPD
with respectively without productive cough. Separate ana-
lyses were also performed by sex. Survival over time of sub-
jects with and without COPD with respectively without
productive cough is illustrated by a Kaplan Meier curve. Non-
COPD and COPD with respectively without productive cough
was analysed as risk factors for death expressed as Hazard
Ratio (HR) using 95% confidence intervals (CI) for statistical
significance in a Cox regression model including the co-
variates sex, age, BMI, smoking habits and heart disease.
Similar analyses were also performed stratified by sex.Results
Baseline characteristics
Productive cough and exacerbations during the last 12
months were significantly more common in COPD compared
to non-COPD (42.8 vs. 23.5%, p < 0.001 and 20.7 vs. 9.0%,
p < 0.001). There was no significant difference regarding
heart disease when comparing COPD and non-COPD, 18.6%
and 16.1% (pZ 0.139). Productive cough was more common
in men than women, significantly so in COPD, but without
reaching statistical significance in non-COPD (Table 1).
Subjects with and without productive cough
Subjects with productive cough were older compared to
those without in both COPD and non-COPD. ‘Any exacerba-




n Z 542 n Z 451
Smoking habits
Non smoker 94(17.5) 138(30.8)
Ex smoker 269(50.2) 152(33.9)
Smoker 173(32.2) 158(35.3) <0
Prod cough 260(48.0) 165(36.6) <0
Exacerbations
Any 108(19.9) 98(21.7) 0
Frequentb 45(8.3) 40(8.9) 0




3e4 38(7.0) 41(9.1) 0
Mortality 148(27.3) 83(18.4) 0
A P-value of <0.05 was regarded as statistically significant.
a Comparing men and women.
b Two or more during the last twelve months.productive cough in both COPD and non-COPD (Table 2). This
pattern was similar in men and women (Fig. 1).
Risk factors for exacerbations
In a multivariate model adjusting for sex, smoking habits,
age, BMI, and heart disease there was an increased risk for
‘any exacerbation’ in non-COPD with productive cough (OR
4.13, 95% CI 2.61e6.54), COPD without and with productive
cough (OR 2.85, 95% CI 1.92e4.23), and (OR 9.25 95% CI
6.23e13.75, respectively) when compared to non-COPD-
subjects without productive cough. Analyses performed
separately by sex showed similar risk factor pattern for men
and women (Table 3).
Mortality
Mortality was significantly higher in COPD compared to non-
COPD (23.3 vs. 17.6%, p Z 0.002). Men had a higher mor-
tality compared to women in both COPD and non-COPD
(Table 1). Subjects with productive cough had higher mor-
tality compared to those without, in both COPD and non-
COPD (Table 2). Survival over time in COPD and non-COPD
with respectively without productive cough is illustrated
by Kaplan-Maiyer curves (Fig. 2). Mortality was highest
among COPD-subjects with productive cough, followed by
non-COPD subjects with productive cough.
COPD-subjects with productive cough had significantly
increased risk for death when analysed in a multivariate
Cox regression model adjusting for sex, increasing age, BMI,
smoking habits and heart disease (HR 1.48, 95% CI
1.13e1.94). In corresponding analyses stratified by sex,
men with COPD and productive cough had significantly
increased risk for death (HR 1.63, 95% CI 1.17e2.26) while
the increased risk for death observed for women with COPD
and productive cough did not reach statistical significance, among subjects with COPD and without COPD, number of
Non-COPD Pa
Men Women
n Z 542 n Z 451
204(38.2) 262(58.7)
271(50.7) 117(26.2)
.001 59(11.0) 67(15.0) <0.001
.001 139(25.6) 94(20.8) 0.075
.485 36(6.6) 53(11.8) 0.005
.812 12(2.2) 18(4.0) 0.026
.001 101(18.6) 59(13.1) 0.018
.028
.001 112(20.7) 63(14.0) 0.006
Table 2 Comparing subjects with and without productive cough in COPD and non-COPD, respectively; age (mean), sex,
smoking habits, heart disease, exacerbations and mortality, number of subjects (percent).
COPD Pa Non-COPD Pa
Productive cough No productive cough Productive cough No productive cough
n Z 394 n Z 599 n Z 209 n Z 784
Sex
Women 165(38.8) 286(50.4) 94(40.3) 357(47.0)
Men 260(61.2) 282(49.6) <0.001 139(59.7) 403(53.0) 0.075
Age, mean (SD) 65.8 64.3 0.034 67.4 63.7 <0.001
Smoking habits
Non smoker 71(16.8) 161(28.6) 97(42.5) 369(49.1)
Ex smoker 162(38.4) 259(46.1) 90(39.5) 298(39.6)
Smoker 189(44.8) 142(25.3) <0.001 41(18.0) 85(11.3) 0.022
Exacerbations
Any 126(29.6) 80(14.1) <0.001 45(19.3) 44(5.8) <0.001
Frequentb 60(14.1) 25(4.4) <0.001 18(7.7) 12(1.6) <0.001




3e4 49(11.5) 30(5.3) <0.001
Mortality 124(29.2) 107(18.8) <0.001 54 (23.2) 121(15.9) 0.011
A P-value of <0.05 was regarded as statistically significant.
a Comparing subject with and without productive cough.
b Two or more during the last twelve months.
Subjects with COPD and productive cough 91(HR 1.23, 95% CI 0.76e1.99) (Table 4). Additional analyses
could not demonstrate any significant interaction by sex
and productive cough.
Sensitivity analysis
Affirmative answer to the question used to define produc-
tive cough did not, per se, exclude subjects with more
longstanding symptoms. Thus we made sensitivity analysis
by excluding subjects with productive cough with duration
two years or more. The prevalence of exacerbations was
still significantly higher among subjects with productive
cough compared to those without productive cough, among
subjects with as well as without COPD (36.6% vs. 14.5%,
p < 0.001 and 26.1% vs. 5.6%, p < 0.001). Productive coughFigure 1 Proportion (%) reporting ’any exacerbation’,
comparing subjects with and without productive cough (prc),
in COPD and non-COPD, respectively, and by sex. *p < 0.05.was associated to significantly increased risk for exacer-
bations also after adjustment for sex, smoking habits and
COPD, and of similar magnitude in men and women in an-
alyses stratified for sex. The mortality was higher among
subjects with productive cough compared to those without
productive cough, among subjects with as well as without
COPD, but without reaching statistical significance (22.0%
vs.18.3%, p Z 0.568 and 17.4% vs. 16.1%, p Z 0.870).
Further, there was no significant difference in prevalence
of exacerbations when comparing subjects with productive
cough less than two years and those with productive cough
with duration two years or more, in either COPD or non-
COPD-subjects. Neither did corresponding analyses of mor-
tality demonstrate any significant differences.
Discussion
In this population-based study productive cough was
related to an increased risk for exacerbations in both COPD
and non-COPD. The increased risk for exacerbation was
present independent of other common risk factors as
smoking habits and age. COPD-subjects with productive
cough had the highest risk for exacerbations, among men as
well as among women. In both COPD and non-COPD, the
mortality was higher in subjects with productive cough than
those without, and higher in men compared to in women.
Subjects with COPD and productive cough had an increased
risk for death also when adjusted for known risk factors
such as sex, age, BMI, smoking habits and heart disease.
Chronic bronchitis is, like COPD, an under-diagnosed
condition, and only every other subject with chronic
bronchitis reported a physician-diagnosis [10]. Even though
tobacco smoke and age are the most well known risk factors
Table 3 Productive cough (prc) and COPD evaluated as risk factors for ‘any exacerbation during the last 12 months’, analyses
also performed stratified by sex, in a multiple logistic regression modela (OR, 95% CI).
‘Any exacerbation during the last 12 months’
All subjects Men Women
N Z 1986 N Z 1084 N Z 902
Or 95% CI Or 95% CI Or 95% CI
Women 1
Men 0.61 0.46e0.80
Non-COPD prc 1 1 1
Non-COPD þprc 4.13 2.61e6.54 4.83 2.34e9.98 4.09 2.21e7.55
COPD prc 2.85 1.92e4.23 4.38 2.30e8.32 2.20 1.32e3.67
COPD þprc 9.25 6.23e13.75 12.34 6.62e22.99 7.88 4.57e13.59
A P-value of <0.05 was regarded as statistically significant.
a Multivariate model adjusting for age, BMI, smoking habits and heart disease.
92 A. Lindberg et al.for COPD and chronic bronchitis, these conditions have also
been reported among non-smokers [19,20]. When evalu-
ating the prognostic impact of bronchitis symptoms, most
often the definition of chronic bronchitis, cough and
phlegm on most days during three months in two successive
years has been used [5,6,21,22]. Also cough and phlegm on
most days during three months without requirement of two
years duration was related to accelerated decline in FEV1
decline and increased hospitalisations in the Copenhagen
City heart study [23]. Productive cough, synonymous with
reported ‘cough and phlegm’ was likewise related to worse
outcome, i.e. increased mortality and decline in lung
function among smokers with mild to moderate obstructive
lung function impairment included in the Lung Health study
[12]. However, it should be noted that subjects with more
longstanding symptoms were not excluded in any of the two
referred studies [12,23].
We have used the term productive cough, defined as
cough and phlegm on most days during at least three
months during the last year, similar to the definitions used
in the above-referred studies [12,23]. Productive cough wasFigure 2 Kaplan-Maiyer curves expressing survival in sub-
jects with and without COPD, with respectively without pro-
ductive cough (prc).common, reported by two out of five subjects with COPD,
and one out of five among those without COPD, in com-
parison to 31% in the COPD-population of the Lung Health
study [12] and around 10% in the general population sample
of the Danish study [23]. We found a higher prevalence of
productive cough among men than among women, and the
large difference can hardly be explained by under reporting
even though under reporting of bronchitis symptoms among
women has been discussed in a quite recent editorial in the
European Respiratory Journal [24].
The relationship between chronic bronchitis and COPD-
exacerbations is well recognized [6,22], but we found that
including also a shorter history of cough and phlegm, such
as productive cough, was related to exacerbations not only
in COPD, but also in non-COPD, and in both sexes. Among
subject with productive cough, every third with COPD, and
one out of five without COPD had ‘any exacerbation’, and
close to every second of them was a ‘frequent exacerbator’
independent of COPD or not. Notably, COPD-subjects with
productive cough had the highest risk for exacerbations in
both sexes. In the PLATINO study sex differences were not
evaluated, but every fifth subject with COPD and chronic
bronchitis reported at least one exacerbation during the
last year [21]. In the Copenhagen City Heart study, the
relative risk for hospitalisation due to COPD exacerbations
was increased five-fold among subjects with ‘chronic mucus
hypersecretion’, and of similar magnitude in men and
women [23]. Heterogeneous definition of exacerbations and
definitions of bronchitis symptoms has to be taken into
account when interpreting data [6,11,21,26]. For compar-
ison to the above-referred population-based studies, the
prevalence of chronic bronchitis was very high, nearly 75%,
in a large but highly selected COPD-population (n Z 433)
recruited from pulmonary units, and more than every sec-
ond of those with chronic bronchitis was a frequent exac-
erbator [22]. However, our population-based study show
that including also less longstanding bronchitis symptoms,
such as productive cough, is clinically important, increasing
the risk for exacerbations defined as contact with health
care due to respiratory complaints. Of importance, the
sensitivity analyses strengthen our results as the increased
risk for exacerbations remained in both men and women
also after excluding subjects with productive cough with
duration two years or more.
Table 4 Productive cough (prc) and COPD evaluated as risk factors for mortality among all subjects and stratified by sex in a
multivariate Cox regression analysisa, expressed as hazard ratios (HR) with 95% confidence intervals (95% CI).
Mortality
All subjects Men Women
N Z 1964b N Z 1070 N Z 894
HR 95% CI HR 95% CI HR 95% CI
Women 1
Men 1.56 1.25e1.94
Non-COPD prc 1 1 1
Non-COPD þprc 1.01 0.73e1.41 1.10 0.74e1.65 0.84 0.47e1.51
COPD prc 1.08 0.83e1.42 1.04 0.73e1.49 1.15 0.76e1.74
COPD þprc 1.48 1.13e1.94 1.63 1.17e2.26 1.23 0.76e1.99
A P-value of <0.05 was regarded as statistically significant.
a Multivariate model adjusting for age, BMI, smoking habits and heart disease.
b 22 subjects excluded from the analyses due to missing data on smoking habits.
Subjects with COPD and productive cough 93Overall-mortality among subjects with COPD in the
population is increased [14,25] and cardiovascular co-
morbidity increase the risk for death [25]. In a Southern
Swedish follow up of more than 22,000 middle-aged sub-
jects, chronic bronchitis increased the risk for death among
women with GOLD grade 2 and in men with GOLD grade 1
when subjects with co-morbidities as cardiovascular dis-
eases were excluded [26]. In a 20-year follow-up of the
OLIN first population based cohort chronic bronchitis as
well as heart disease increased the risk for death among
subjects with COPD [5]. In our study presence of productive
cough affected mortality in both COPD and non-COPD; the
all-cause mortality was highest among COPD-subjects with
productive cough, followed by non-COPD subjects with
productive cough. Subjects with COPD and productive
cough had an increased risk for death also in the presence
of other known risk factors for death as male gender,
smoking and heart disease. In analyses stratified by sex, the
increased risk for death did reach statistical significance
among men but not among women. These findings do not
ensure any difference between the sexes, but the results
indicate that there may be sex differences; thus there is a
need for further studies. Even though the statistical sig-
nificance was lost, there was also a signal from the sensi-
tivity analysis suggesting that mortality is higher in subjects
with COPD and chronic productive cough than those
without also after excluding those with productive cough
duration two years or more. For comparison, in the previ-
ously referred studies where ‘cough and phlegm’ was
associated with worse prognosis [12,23], less than two years
duration of symptoms was needed to fulfil the definition of
symptoms, however, it was not stated that subjects with
more long standing symptoms were excluded. Phenotyping
based on clinical characteristics such as presentation of
symptoms is an important future research area and may
give us simple and cheap tools of high prognostic value.
Further studies of not only all-cause mortality but also
cause of death in relation to clinical phenotypes can pro-
vide valuable information useful for risk assessment in
clinical practise.
We found a high prevalence of productive cough also
among non-COPD subjects, and subjects with respiratory
symptoms may be over-represented in this non-COPDpopulation. On the other hand, also a healthy survivor
effect has to be taken into account, as the original cohorts
from whom the study population was identified were
recruited during the eighties and the nineties [14]. In this
context, it has to be emphasized that productive cough may
be of importance not only among subjects with COPD but
also among non-COPD subjects, identifying individuals with
a higher risk of developing COPD [27e29], i.e. productive
cough may represent early signs of COPD. Further, non-
COPD subjects with productive cough had more exacerba-
tions compared to those without, and it has recently been
shown that the burden of exacerbation-like events in
important also among non-COPD subjects, negatively
affecting health status and increasing health care utiliza-
tion [30].
The strength of this study is the large number of subjects
with COPD identified by standardized spirometry, compa-
rable to that of the NHANES I [31], and also the PLATINO
study [21]. The distribution of disease severity corresponds
to what is known for the general population [8], including a
majority GOLD grades 1 and 2. The sex- and age matched
reference population without obstructive lung function
impairment gives an excellent opportunity to evaluate the
impact of productive cough comparing COPD and non-
COPD. The large COPD-cohort gives statistical power
enough to gain new data, such as evaluating not only the
prognostic significance of a symptom as productive cough,
but also to conduct analyses stratified by sex. Most often
sex is treated as a confounder when estimating risk [12,21],
but in this study the analyses stratified by sex allows us to
consider sex-specific risk factor patterns. However, there
are limitations, such as that the self-reported information
about heart disease and exacerbations were not validated
by medical records, and a certain recall bias cannot be
excluded. Further, our definition of exacerbations did
neither include use of oral steroids or antibiotics, nor need
for hospitalization but on the other hand, a highly clinical
and health economically relevant distinction, namely
symptoms that prompted contact with health care. More-
over, the observed association between productive cough
and exacerbation is based on cross-sectional data, and we
cannot exclude that the reported symptoms in some cases
are results of an exacerbation. The spirometric criteria to
94 A. Lindberg et al.define COPD can also be discussed, and today the lower
limit of normal, LLN, is recommended to define COPD in
epidemiological studies [32]. However, the current study
was designed shortly after the shift of the millennium when
the fixed ratio, FEV1/FVC < 0.70, was recommended to
define COPD after the launch of the GOLD guidelines in
1997. It is well known that the fixed ratio will overestimate
COPD among elderly, and as a consequence, GOLD 1 may
include non-smokers without respiratory symptoms, espe-
cially among elderly. Still the fixed ratio is commonly used
in health care, and our results can be interpreted in rela-
tion to clinical practice, even though the weaknesses of the
fixed ratio always have to be taken into account.
In conclusion, in this population-based study productive
cough was more common in men than in women, and
associated to exacerbations in both sexes among subjects
with as well as without COPD. Subjects with COPD and
productive cough had the highest risk for exacerbations also
after adjustment for other common risk factors, and also
increased mortality. These findings imply that productive
cough is a highly clinically relevant symptom; a marker of
poorer prognosis in COPD that, by definition, can be iden-
tified earlier than chronic bronchitis.
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